These positive results, along with the demonstration of the induction of a specific anti-tyrosinase immune response in some DNA vaccinated dogs [139], led, in 2010, to the approval by the United States Department of Agriculture (USDA) of the first anti-human tyrosinase DNA vaccine (Oncept, Merial) for the treatment of melanoma affected dogs. The gene discussed is TYR; the disease is melanoma.